Sensei Biotherapeutics (SNSE) Competitors $9.14 -0.13 (-1.36%) As of 07/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. ATNM, MURA, SCLX, GRCE, STTK, ITRM, ANVS, PLUR, MDCX, and KPTIShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Actinium Pharmaceuticals (ATNM), Mural Oncology (MURA), Scilex (SCLX), Grace Therapeutics (GRCE), Shattuck Labs (STTK), Iterum Therapeutics (ITRM), Annovis Bio (ANVS), Pluri (PLUR), Medicus Pharma (MDCX), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Its Competitors Actinium Pharmaceuticals Mural Oncology Scilex Grace Therapeutics Shattuck Labs Iterum Therapeutics Annovis Bio Pluri Medicus Pharma Karyopharm Therapeutics Actinium Pharmaceuticals (NYSE:ATNM) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Is ATNM or SNSE more profitable? Sensei Biotherapeutics' return on equity of -66.72% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Sensei Biotherapeutics N/A -66.72%-57.10% Does the media favor ATNM or SNSE? In the previous week, Actinium Pharmaceuticals had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 2 mentions for Actinium Pharmaceuticals and 0 mentions for Sensei Biotherapeutics. Actinium Pharmaceuticals' average media sentiment score of 0.95 beat Sensei Biotherapeutics' score of 0.00 indicating that Actinium Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Actinium Pharmaceuticals Positive Sensei Biotherapeutics Neutral Which has more volatility & risk, ATNM or SNSE? Actinium Pharmaceuticals has a beta of -0.32, suggesting that its stock price is 132% less volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Which has preferable earnings and valuation, ATNM or SNSE? Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.47-0.98Sensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.39 Do institutionals & insiders have more ownership in ATNM or SNSE? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend ATNM or SNSE? Actinium Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 177.78%. Sensei Biotherapeutics has a consensus price target of $90.00, suggesting a potential upside of 891.74%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummarySensei Biotherapeutics beats Actinium Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.39M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.3921.5627.6120.23Price / SalesN/A278.31417.23118.52Price / CashN/A42.7336.8958.10Price / Book0.307.518.035.67Net Income-$30.16M-$55.14M$3.18B$249.21M7 Day Performance5.40%4.61%2.93%3.28%1 Month Performance25.69%4.72%3.75%5.55%1 Year Performance-27.06%5.92%35.20%21.09% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.1994 of 5 stars$9.08-2.1%$90.00+891.7%-27.1%$11.39MN/A-0.3940Gap DownATNMActinium Pharmaceuticals2.7384 of 5 stars$1.40-1.4%$4.00+185.7%N/A$43.67M$81K-1.0130MURAMural Oncology3.0865 of 5 stars$2.47-0.4%$12.00+385.8%-13.7%$42.83MN/A-0.32119News CoverageSCLXScilex1.7329 of 5 stars$5.89-2.6%$455.00+7,625.0%-90.5%$42.06M$56.59M-0.2080GRCEGrace Therapeutics1.769 of 5 stars$2.97flat$12.00+304.0%N/A$41.07MN/A-3.34N/APositive NewsSTTKShattuck Labs2.8583 of 5 stars$0.79-7.3%$7.50+847.2%-77.4%$40.89M$5.72M-0.57100Gap UpITRMIterum Therapeutics1.9069 of 5 stars$1.00-1.5%$9.00+804.5%-15.1%$40.40MN/A-1.0110News CoverageANVSAnnovis Bio1.5195 of 5 stars$2.18+6.3%$30.25+1,287.6%-70.5%$39.95MN/A-1.013PLURPluri3.5591 of 5 stars$4.95-2.8%$12.00+142.4%+2.1%$39.87M$330K-0.90150News CoveragePositive NewsInsider TradeMDCXMedicus Pharma2.2666 of 5 stars$2.99+3.1%$23.50+686.0%N/A$39.36MN/A-2.58N/AAnalyst ForecastKPTIKaryopharm Therapeutics3.8397 of 5 stars$4.31-1.8%$43.20+902.3%-62.8%$37.93M$145.24M-0.32380 Related Companies and Tools Related Companies ATNM Alternatives MURA Alternatives SCLX Alternatives GRCE Alternatives STTK Alternatives ITRM Alternatives ANVS Alternatives PLUR Alternatives MDCX Alternatives KPTI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
